Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors

Clinical Cornerstone

Volumn 8, Issue 3, 2007, Pages 53-68

  Gerich, John E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG;

ARTICLE; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; RISK FACTORS; RISK REDUCTION BEHAVIOR; THIAZOLIDINEDIONES;

EID: 42649094502     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(07)80028-7     Document Type: Article

References (95)

1. Watson K. Managing cardiometabolic risk: An evolving approach to patient care. Crit Pathw Cardiol 6 (2007) 5-14
2. ADA. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
3. Haffner S., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
4. Fox C., Coady S., Sorlie P., et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 115 (2007) 1544-1550
5. Buse J., Ginsberg H., Bakris G., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30 (2007) 162-172
6. Nathan D. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1342-1349
7. Coutinho M., Gerstein H., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 22 (1999) 233-240
8. Carmena R., and Betteridge D. Statins and diabetes. Semin Vasc Med 4 (2004) 321-332
9. Yusuf S., Hawken S., Ounpuu S., et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364 (2004) 937-952
10. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67 (2007) 997-1026
11. Erdmann E. Diabetes and cardiovascular risk markers. Curr Med Res Opin 21 Suppl 1 (2005) S21-S28
12. Eckel R., Kahn R., Robertson R., and Rizza R. Preventing cardiovascular disease and diabetes: A call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 29 (2006) 1697-1699
13. Schneider C. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. Curr Med Res Opin 22 Suppl 2 (2006) S15-S26
14. Saydah S., Fradkin J., and Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
15. Massi-Benedetti M. Changing targets in the treatment of type 2 diabetes. Curr Med Res Opin 22 Suppl 2 (2006) S5-S13
16. Jeerakathil T., Johnson J., Simpson S., and Majumdar S. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: A population-based cohort study. Stroke 38 (2007) 1739-1743
17. Levy D., Larson M., Vasan R., et al. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
18. Masoudi F., and Inzucchi S. Diabetes mellitus and heart failure: Epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99 (2007) 113B-132B
19. Movahed M. Diabetes as a risk factor for cardiac conduction defects: A review. Diabetes Obes Metab 9 (2007) 276-281
20. Bolaman Z., Kok F., Kadikoylu G., et al. The changes of coagulation parameters and microvascular complications in diabetes mellitus. Endocrinologist 17 (2007) 196-199
21. Gami A., Witt B., Howard D., et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
23. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
24. 1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 147 (2007) 417-422
25. Unger J. Practical strategies for achieving targeted glycemic control in patients with type 2 diabetes. J Fam Pract 55 (2006) S25-S32
26. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Chapter 6: Glucose control levels (October 16, 2007). http://www.idf.org/webdata/docs/GGT2D%2006%20Glucose%20control%20levels.pdf Accessed
27. LeRoith D., and Smith D. Monitoring glycemic control: The cornerstone of diabetes care. Clin Ther 27 (2005) 1489-1499
28. Woerle H., Tenner S., Irsigler A., et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 77 (2007) 280-285
29. Bolen S., Feldman L., Vassy J., et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007) 386-399
30. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 287 (2002) 360-372
31. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
32. ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus. Endocrine Pract 13 (2007) 260-268
33. Arauz-Pacheco C., Parrott M., and Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 25 (2002) 134-147
34. Geiss L., Rolka D., and Engelgau M. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 22 (2002) 42-48
35. Vijan S., and Hayward R. Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138 (2003) 593-602
36. Tan A., Kuppuswamy S., Whaley-Connell A., et al. Recommendations for special populations-the treatment of hypertension in diabetes mellitus. Endocrinologist 14 (2004) 368-381
37. Choe H., Townsend K., Blount G., et al. Treatment and control of blood pressure in patients with diabetes mellitus. Am J Health Syst Pharm 64 (2007) 97-103
38. Kengne A., Patel A., Barzi F., et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 25 (2007) 1205-1213
39. Almgren T., Wilhelmsen L., Samuelsson O., et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: Results from a 28-year follow-up. J Hypertens 25 (2007) 1311-1317
40. Adler A., Stratton I., Neil H., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 321 (2000) 412-419
41. Smith E., and Ashiya M. Antihypertensive therapies. Nat Rev Drug Discov 6 (2007) 597-598
42. Sowers J., and Reed J. 1999 Clinical Advisory Treatment of Hypertension and Diabetes. J Clin Hypertens (Greenwich) 2 (2000) 132-133
43. Dobesh P. Managing hypertension in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 63 (2006) 1140-1149
44. Bakris G., Williams M., Dworkin L., et al., National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Special report. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kid Dis 36 (2000) 646-661
45. Bakris G. The importance of blood pressure control in the patient with diabetes. Am J Med 116 Suppl 1 (2004) 30-38
46. Sowers J., Epstein M., and Frohlich E. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 37 (2001) 1053-1059
47. Junga K., Merlo J., Gullberg B., et al. Residual risk for acute stroke in patients with type 2 diabetes and hypertension in primary care: Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab 8 (2006) 492-500
48. Haffner S. Dyslipidemia management in adults with diabetes. Diabetes Care 27 Suppl 1 (2004) S68-S71
49. Davidson M., and Robinson J. Safety of aggressive lipid management. J Am Coll Cardiol 49 (2007) 1753-1762
50. Verges B. Diabetic dyslipidaemia: Insights for optimizing patient management. Curr Med Res Opin 21 Suppl 1 (2005) S29-S40
51. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
52. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
53. Goldberg R., Mellies M., Sacks F., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The Care Investigators. Circulation 98 (1998) 2513-2519
54. Haffner S., Alexander C., Cook T., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
55. Rubins H., Robins S., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
56. Koskinen P., Manttari M., Manninen V., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
57. Hanefeld M. Outcome studies in type 2 diabetes. Curr Med Res Opin 21 Suppl 1 (2005) S41-S48
58. LaRosa J., Grundy S., Waters D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
59. Meinert C., Knatterud G., Prout T., and Klimt C. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 Suppl (1970) 789-830
60. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
61. Hanefeld M., Fischer S., Schmechel H., et al., Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14 (1991) 308-317
62. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
63. Colhoun H., Betteridge D., Durrington P., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
64. Lewis E., Hunsicker L., Clarke W., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
65. Brenner B., Cooper M., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
66. Knopp R., d'Emden M., Smilde J., and Pocock S. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
67. Dormandy J., Charbonnel B., Eckland D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
68. Wilcox R., Bousser M., Betteridge D., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
69. Keech A., Simes R., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366 (2005) 1849-1861
70. Chapman R., Benner J., Petrilla A., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165 (2005) 1147-1152
71. Sigal L. Basic science for the clinician 44: Atherosclerosis: An immunologically mediated (autoimmune?) disease. J Clin Rheumatol 13 (2007) 160-168
72. Biondi-Zoccai G., Abbate A., Liuzzo G., and Biasucci L. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41 (2003) 1071-1077
73. Moreno P., Murcia A., Palacios I., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
74. Nesto R. Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
75. Van Gaal L., Mertens I., and De Block C. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
76. Haire-Joshu D., Glasgow R., and Tibbs T. Smoking and diabetes. Diabetes Care 22 (1999) 1887-1898
77. Al-Delaimy W., Willett W., Manson J., et al. Smoking and mortality among women with type 2 diabetes: The Nurses' Health Study cohort. Diabetes Care 24 (2001) 2043-2048
78. Wannamethee S., Shaper A., and Perry I. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 24 (2001) 1590-1595
79. Haire-Joshu D., Glasgow R., and Tibbs T. Smoking and diabetes. Diabetes Care 26 Suppl 1 (2003) S89-S90
80. Gunton J., Davies L., Wilmshurst E., et al. Cigarette smoking affects glycemic control in diabetes. Diabetes Care 25 (2002) 796-797
81. Kelley D., Kuller L., McKolanis T., et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27 (2004) 33-40
82. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
83. Dansinger M., Tatsioni A., Wong J., et al. Meta-analysis: The effect of dietary counseling for weight loss. Ann Intern Med 147 (2007) 41-50
84. Wolf A., and Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg 17 (2007) 910-919
85. Keating G., and Croom K. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 (2007) 121-153
86. Verges B. Fenofibrate therapy and cardiovascular protection in diabetes: Recommendations after FIELD. Curr Opin Lipidol 17 (2006) 653-658
87. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
88. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
89. Dormandy J., Charbonnel B., Eckland D., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
90. Lyseng-Williamson K. Sitagliptin. Drugs 67 (2007) 587-597
91. Rosenstock J., Brazg R., Andryuk P., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. Clin Ther 28 (2006) 1556-1568
92. Brazg R., Xu L., Dalla Man C., et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9 (2007) 186-193
93. Aschner P., Kipnes M., Lunceford J., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
94. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
95. Cvetkovic R., and Plosker G. Exenatide: A review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67 (2007) 935-954